NASDAQ: EOLSEvolus Inc Stock
$12.93+0.32 (+2.54%)
Updated May 31, 2024
EOLS Price
$12.93
Fair Value Price
N/A
Market Cap
$809.55M
52 Week Low
$7.07
52 Week High
$15.43
P/E
-12.43x
P/B
43.89x
P/S
3.75x
PEG
N/A
Dividend Yield
N/A
Revenue
$219.70M
Earnings
-$60.00M
Gross Margin
69.3%
Operating Margin
-20.05%
Profit Margin
-27.3%
Debt to Equity
11.26
Operating Cash Flow
-$24M
Beta
1.13
Next Earnings
Jul 31, 2024
Ex-Dividend
N/A
Next Dividend
N/A
EOLS Overview
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Zen Score
–
Industry Average (24)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how EOLS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EOLS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
EOLS is poor value based on its book value relative to its share price (43.89x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.17x)
P/B vs Industry Valuation
EOLS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more EOLS due diligence checks available for Premium users.
Be the first to know about important EOLS news, forecast changes, insider trades & much more!
EOLS News
Valuation
EOLS fair value
Fair Value of EOLS stock based on Discounted Cash Flow (DCF)
Price
$12.93
Fair Value
$47.28
Undervalued by
72.65%
EOLS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
EOLS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-12.43x
Industry
0.92x
Market
28.44x
EOLS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
43.89x
Industry
2.17x
EOLS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
EOLS's financial health
Profit margin
Revenue
$59.3M
Net Income
-$13.1M
Profit Margin
-22.1%
EOLS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
EOLS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$226.2M
Liabilities
$207.7M
Debt to equity
11.26
EOLS's short-term assets ($150.27M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EOLS's long-term liabilities ($160.93M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EOLS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
EOLS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.6M
Investing
-$797.0k
Financing
$45.7M
EOLS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
EOLS vs Pharmaceutical Stocks
Evolus Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.